Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Two-Part Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

NCT07027514 is registered in ClinicalTrials.gov with Ankyra Therapeutics, Inc as lead sponsor.

NCT NCT07027514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07027514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Two-Part Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Lead sponsor
Ankyra Therapeutics, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
October 22, 2025
Completion date
December 31, 2028
Enrollment
60 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer